You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯康生物科技集團(00690.HK):北京博康健與國藥威奇達及蘇州營力達成戰略合作
格隆匯 04-15 17:46

格隆匯4月15日丨聯康生物科技集團(00690.HK)發佈公告,公司全資附屬公司,北京博康健、國藥威奇達、蘇州營力達成戰略合作,根據戰略合作協議安排,蘇州營力負責阿卡波糖原料藥早期研發,國藥威奇達負責完成阿卡波糖原料藥的產業化開發、生產和供應,而北京博康健獲得至少十年穩定的阿卡波糖原料藥供應,用於產品商業化。

本次合作,有利於各方發揮各自優勢,通過產業鏈上下游緊密合作,提高生產效率,強化成本優勢和市場優勢,努力以更優質的藥品,服務於更廣泛的中國糖尿病患者,力爭使北京博康健入選阿卡波糖全國帶量採購,降低醫保支付壓力,充分實現產品的臨牀價值,社會價值和市場價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account